There has been outbreaks of strange diseases throughout the world. This has called for the need to invest more in the field of medicine. A lot of research has been done and still needs to be done in order to curb, cure or manage this diseases. The explosive growth in this field of medicine is being able to target specific mutations or genotypes to treat diseases in unique ways. This leads to extending and saving lives.
Dr. Scott Rocklage has contributed so much in this field of management. He is a more productive entrepreneur who is also very well organized with regards to calendaring, prioritization and time management.
Scott Rocklage is a B.S. in Chemistry graduate from the University of California, Berkeley and also holds a PhD in Chemistry from the Massachusetts Institute of Technology (MIT). Dr. Rocklage who is based in the Boston, MA office was involved in the invention or co-invention of over 30 U.S. patents and greater than 100 peer-reviewed publications.
His main business is the 5AM Ventures which is a life science-based venture capital firm. Dr. Rocklage works with entrepreneurs such as business-executives, scientists or physicians with the aim of assisting them in shaping their ideas into potential medicines to cure or manage the unmet medical needs.
Scott M. Rocklage, Ph.D. joined 5AM Ventures in 2003 as a Venture Partner. Because of his hard work he was promoted and became the Managing Partner of the 5AM Ventures in 2004. Dr. Rocklage has over 20 years of healthcare management experience.
His strategic leadership skills enabled him handle his responsibilities well which led to the fruitful approval of three U.S. New Drug Applications by the FDA, and also managed to enter six drug candidates into clinical trials. Many companies envied his efforts in doing work thus he has worked and headed so many companies.
Dr. Rocklage has served as a Chairman and CEO of Cubist Pharmaceuticals, President and CEO of Nycomed Salutar, President, CEO and Chairman of Nycomed Interventional and has also held various R&D positions at Salutar and Catalytica. He was the former Executive Chairman of Ilypsa and Miikana.
Currently, Dr. Rocklage is serving as the Board Chairman of Achaogen, Relypsa and Semprus as well as on the Boards of WaveRx, Pulmatrix and Variation and the Board of Associates at the Whitehead Institute.